JP2024519496A5 - - Google Patents

Info

Publication number
JP2024519496A5
JP2024519496A5 JP2023567962A JP2023567962A JP2024519496A5 JP 2024519496 A5 JP2024519496 A5 JP 2024519496A5 JP 2023567962 A JP2023567962 A JP 2023567962A JP 2023567962 A JP2023567962 A JP 2023567962A JP 2024519496 A5 JP2024519496 A5 JP 2024519496A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
monocyclic
alkynyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023567962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519496A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/027888 external-priority patent/WO2022235945A1/en
Publication of JP2024519496A publication Critical patent/JP2024519496A/ja
Publication of JP2024519496A5 publication Critical patent/JP2024519496A5/ja
Pending legal-status Critical Current

Links

JP2023567962A 2021-05-05 2022-05-05 ブルトンのチロシンキナーゼの分解を標的化するための化合物 Pending JP2024519496A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184439P 2021-05-05 2021-05-05
US63/184,439 2021-05-05
PCT/US2022/027888 WO2022235945A1 (en) 2021-05-05 2022-05-05 Compounds for targeting degradation of bruton's tyrosine kinase

Publications (2)

Publication Number Publication Date
JP2024519496A JP2024519496A (ja) 2024-05-14
JP2024519496A5 true JP2024519496A5 (https=) 2025-05-14

Family

ID=82115630

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023567962A Pending JP2024519496A (ja) 2021-05-05 2022-05-05 ブルトンのチロシンキナーゼの分解を標的化するための化合物

Country Status (17)

Country Link
US (1) US20240287076A1 (https=)
EP (1) EP4333899A1 (https=)
JP (1) JP2024519496A (https=)
KR (1) KR20240017814A (https=)
CN (1) CN117580592A (https=)
AR (1) AR125768A1 (https=)
AU (1) AU2022268977A1 (https=)
BR (1) BR112023023065A2 (https=)
CA (1) CA3217417A1 (https=)
CL (1) CL2023003258A1 (https=)
CO (1) CO2023016743A2 (https=)
IL (1) IL308219A (https=)
JO (1) JOP20230274A1 (https=)
MX (1) MX2023013046A (https=)
TW (1) TW202309039A (https=)
UY (1) UY39756A (https=)
WO (1) WO2022235945A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3060629T3 (en) * 2019-10-30 2026-03-27 Biogen Ma Inc Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase
TW202132316A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ras抑制劑
CA3194067A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Ras inhibitors
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
JP7805983B2 (ja) 2022-03-22 2026-01-26 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン
AU2023278399A1 (en) 2022-06-02 2024-12-19 Xizang Haisco Pharmaceutical Co., Ltd. Compound for inhibiting or degrading bcl6 and use thereof in pharmaceutics
CN121311479A (zh) 2023-01-09 2026-01-09 蒙特罗萨治疗股份公司 Vav1的靶向降解
CN120202200A (zh) * 2023-06-01 2025-06-24 标新生物医药科技(上海)有限公司 基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用
EP4735438A2 (en) 2023-06-30 2026-05-06 Merck Patent GmbH Heterobifunctional compounds for the degradation of kras
EP4735452A2 (en) 2023-06-30 2026-05-06 Merck Patent GmbH Heterobifunctional compounds for the degradation of kras protein
WO2025026455A1 (zh) 2023-08-03 2025-02-06 海思科医药集团股份有限公司 一种多环并环btk降解剂及其在医药上的应用
CN121773112A (zh) 2023-08-17 2026-03-31 海思科医药集团股份有限公司 一种氰基芳香环衍生物及其在医药上的应用
CN121405700A (zh) * 2024-07-26 2026-01-27 苏州亚盛药业有限公司 Btk降解剂及其用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
RU2738833C9 (ru) 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6817962B2 (ja) 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
EP3270917A4 (en) 2015-03-18 2018-08-08 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
CA2988414C (en) 2015-06-04 2023-09-26 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3319944A4 (en) 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
BR112017028269A2 (pt) 2015-07-13 2018-09-04 Arvinas Inc composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
GB201516243D0 (en) 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
SG11201808728QA (en) 2016-04-06 2018-11-29 Univ Michigan Regents Mdm2 protein degraders
KR20180132861A (ko) 2016-04-12 2018-12-12 더 리젠츠 오브 더 유니버시티 오브 미시간 Bet 단백질 분해제
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
US20180072711A1 (en) 2016-09-15 2018-03-15 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
CN110506039A (zh) 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
BR112019011200B1 (pt) 2016-12-01 2021-12-28 Arvinas Operations, Inc Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
KR20250117470A (ko) 2016-12-23 2025-08-04 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
JP2020505327A (ja) 2016-12-23 2020-02-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. Egfrタンパク質分解標的化キメラ分子およびその関連する使用方法
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
UY37559A (es) * 2017-01-06 2018-05-31 Pharmacyclics Llc Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton
BR112019015312A2 (pt) 2017-01-26 2020-03-10 Arvinas Operations, Inc. Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados
IL312367A (en) 2017-01-31 2024-06-01 Arvinas Operations Inc Cereblon ligands and bifunctional compounds comprising the same
WO2018226542A1 (en) 2017-06-09 2018-12-13 Arvinas, Inc. Modulators of proteolysis and associated methods of use
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
EP3658548A1 (en) 2017-07-28 2020-06-03 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
EP3774808A1 (en) * 2018-03-26 2021-02-17 Novartis AG 3-hydroxy-n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives
CN111936498B (zh) * 2018-03-26 2024-04-16 诺华股份有限公司 N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
US20190300521A1 (en) 2018-04-01 2019-10-03 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
IL302595A (en) 2018-04-13 2023-07-01 Arvinas Operations Inc Servalon ligands and bifunctional compounds containing them
EP3781156A4 (en) 2018-04-16 2022-05-18 C4 Therapeutics, Inc. SPIROCYCLIC COMPOUNDS
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
ES2995214T3 (en) 2019-03-06 2025-02-07 C4 Therapeutics Inc Heterocyclic compounds for medical treatment
WO2020210630A1 (en) 2019-04-12 2020-10-15 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
CN114521196A (zh) * 2019-09-16 2022-05-20 诺华股份有限公司 双官能团降解剂及其使用方法
WO2021053459A1 (ja) * 2019-09-20 2021-03-25 株式会社半導体エネルギー研究所 表示装置、表示モジュール、及び電子機器
EP4051679B1 (en) * 2019-10-30 2025-08-06 Biogen MA Inc. Condensed pyridazine or pyrimidine as btk inhibitors
ES3060629T3 (en) * 2019-10-30 2026-03-27 Biogen Ma Inc Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase
EP4077319A1 (en) 2019-12-20 2022-10-26 Calico Life Sciences LLC Protein tyrosine phosphatase degraders and methods of use thereof
CN116589466B (zh) * 2020-04-30 2025-08-15 百济神州有限公司 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法

Similar Documents

Publication Publication Date Title
JP2024519496A5 (https=)
AU2013266110C1 (en) Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JP4853284B2 (ja) チアゾール誘導体
JP4648703B2 (ja) 医薬としての新規なアミノインダゾール誘導体及びこれらを含む医薬組成物
ES2677996T3 (es) Nuevas indazolcarboxamidas, procedimiento para su preparación, preparaciones farmacéuticas que contienen las mismas, así como su uso para la preparación de medicamentos
EP1240160A1 (en) Substituted pyridazines having cytokine inhibitory activity
JP2022533398A5 (https=)
JP2023525137A5 (https=)
JP7337813B2 (ja) 肝再生促進又は肝細胞死の抑制もしくは防止のためのプロテインキナーゼmkk4阻害剤
AU2007225678A1 (en) Quinolone derivative or pharmaceutically acceptable salt thereof
AU2024202860A1 (en) Metalloenzyme inhibitor compounds
JP2010539110A5 (https=)
JP2018529745A5 (https=)
CA3042684A1 (en) Azole amides and amines as .alpha.v integrin inhibitors
JP2014514302A5 (https=)
JP2023544476A5 (https=)
RU2013154117A (ru) Производные 1-фенил-2-пиридинилалкильных спиртов в качестве ингибиторов фосфодиэстеразы
JP2021528451A5 (https=)
AU2002330096B2 (en) Process for making substituted pyrazoles
WO2018125799A2 (en) Metalloenzyme inhibitor compounds
TW201418264A (zh) 磷酸二酯酶第10a型之新穎抑制劑化合物
JP2022505827A5 (https=)
JP2023526332A5 (https=)
JP2023546226A5 (https=)
JP2024540187A5 (https=)